Search the Newsreel

Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...

This article first appeared on GuruFocus. Total Revenues: Approximately $629 million for Q2 2026. Cabozantinib Franchise Net Product Revenues (US): $573 million, up approximately 10% year-over-year. Global Cabozantinib Franchise Net Product Revenues (Exelixis and partners): $806 million, up approximately 13% year-over-year. CABOMETYX Net Product …

Lazard Asset Management LLC Buys New Position in Expand Energy Corporation $EXE

Lazard Asset Management LLC has acquired a new position in Expand Energy Corporation (NASDAQ:EXE), purchasing 13,520 shares valued at approximately $1.48 million. Institutional investors now collectively own 97.93% of the company. Expand Energy recently reported quarterly EPS of $1.33, surpassing analyst expectations, and declared …

Exelixis (EXEL) Tops Q2 Earnings Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Crexendo, Inc. (CXDO) CTO discloses stock options, RSUs and shares

Crexendo, Inc.'s Chief Technology Officer, Christopher Ryan Aaker, has filed an initial statement of beneficial ownership (Form 3) detailing his equity holdings. His holdings include stock options for 30,000 common shares with varying exercise prices and expiration dates, restricted stock units (RSUs) totaling 42,501 …

Exelixis Q2 2026 earnings: Cabozantinib growth lifts revenue and EPS

Exelixis reported strong Q2 2026 earnings, with revenue reaching $628.7 million, a 10.6% increase year-over-year, and diluted EPS rising to $0.82. This growth was primarily driven by higher sales volume of cabozantinib, though the company lowered its full-year revenue outlook. Exelixis continues to invest …

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Exelixis reported strong second-quarter 2026 financial results, with total revenues reaching $628.7 million and GAAP diluted EPS of $0.82. The company highlighted the continued growth of its cabozantinib franchise and significant progress in its zanzalintinib development program, including ongoing regulatory review for metastatic colorectal …

Transcript : Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026

This article is a transcript of Exelixis, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. During the call, Exelixis updated its fiscal 2026 revenue guidance to $2.50B-$2.55B, lower than FactSet's estimate of $2.60B. The company also reported Q2 revenue of $628.7M and …

Crexendo (NASDAQ:CXDO) Releases Earnings Results, Beats Expectations By $0.02 EPS

Crexendo (NASDAQ:CXDO) announced its quarterly earnings, reporting $0.12 EPS, beating analyst expectations by $0.02, with revenue matching estimates at $24.65 million. Despite positive operational growth, including a 49% increase in second-quarter revenue and significant gains in operating cash flow, the stock experienced a 9.7% …

Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M

Exelixis, Inc. (EXEL) reported its Q2 revenue at $628.7 million, falling short of the FactSet estimate of $636.4 million. The company also updated its fiscal year 2026 revenue guidance to a range of $2.50 billion to $2.55 billion, which is below the FactSet estimate …

Exelixis earnings on deck as generic threat looms

Exelixis Inc. is set to report second-quarter earnings, facing scrutiny over its flagship cancer drug, Cabometyx, due to an escalating patent dispute and the emergence of a generic alternative. Investors are also keenly watching the commercialization prospects for its next-generation pipeline drug, zanzalintinib, and …

Royal Bank of Canada Grows Stock Holdings in Exelixis, Inc. $EXEL

Royal Bank of Canada increased its holdings in Exelixis, Inc. by 24.6% in the first quarter, now owning 694,131 shares valued at approximately $29.8 million. This increase comes as Exelixis reported strong quarterly earnings, beating analyst estimates, with revenue up 10% year-over-year. Despite recent …

Rexel: Statement relating to the total number of shares and voting rights as of July 31, 2026

Rexel Développement SAS Rexel: Statement relating to the total number of shares and voting rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Rules of the French Autorité des marchés financiers Date Number of shares Number …

Lexeo's LX2020 Secures FDA RMAT Tag For PKP2-Associated Arrhythmogenic Cardiomyopathy

(RTTNews) - Lexeo Therapeutics (LXEO) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). PKP2-associated arrhythmogenic cardiomyopathy is a rare inherited heart disease caused …

Lexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy LX2020, intended for PKP2-associated arrhythmogenic cardiomyopathy. This designation was granted based on positive interim data from the ongoing Phase I/II HEROIC-PKP2 trial. LX2020 previously received FDA Orphan Drug and …

B. Riley Adjusts Price Target on Crexendo to $9 From $10, Maintains Buy Rating

B. Riley has revised its price target for Crexendo (CXDO) shares down to $9 from $10, while still maintaining a Buy rating on the stock. This adjustment comes despite the firm's continued positive outlook for the company. The article also mentions recent news about …

Crexendo Q2 2026 earnings: Service revenue drives 49% growth

Crexendo (CXDO) reported a 49% year-over-year revenue increase to $24.6 million in Q2 2026, primarily driven by service revenue. Despite this growth, GAAP diluted EPS declined to $0.03 from $0.04 due to operating expenses growing slightly faster than revenue. The company saw higher non-GAAP …

CXDO|Crexendo Inc|Price:7.450|Chg%:+0.230

Crexendo Inc (CXDO) is a software technology company focused on cloud communication and IT services. The company's stock currently trades at $7.450, up 3.19%, with a market capitalization of $241.33 million. Analysts rate CXDO as a "Buy" with a target price of $11.17, suggesting …

Exelixis (EXEL) Stock Still Looks Cheap On Earnings While Returns Look Rich

Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Earnings call transcript: Crexendo tops Q2 2026 profit view as shares rise

Crexendo Inc. reported strong Q2 2026 results, beating profit expectations with adjusted EPS of $0.12 and matching revenue forecasts at $24.65 million. The company saw a 49% revenue increase year-over-year, driven by the ESI acquisition, and reported its 12th consecutive quarter of GAAP profitability. …

How Exelon’s Q2 Results, Dividend and Grid Investments Could Impact Exelon (EXC) Investors

Crexendo, Inc. Reports Q2 2026 Financial Results: Revenue Growth and Financial Highlights in Latest 10-Q Filing

Crexendo, Inc. reported its Q2 2026 financial results, showing a net income of $1.05 million and significant product revenue growth to $2.45 million, up from $1.20 million in Q2 2025. Despite increased revenue, net income and EPS declined year-over-year, while stockholders' equity and total …

Crexendo Q2 Earnings Call Highlights

Key Points Interested in Crexendo Inc.? Here are five stocks we like better. Strong Q2 growth: Revenue rose 49% year over year to $24.6 million, supported by telecom growth and the ESI acquisition. GAAP net income reached $1.1 million, while adjusted EBITDA increased 46% …

Crexendo (CXDO) Surpasses Q2 Earnings Estimates

Crexendo (CXDO) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Crexendo, Inc. (NASDAQ: CXDO) grows revenue and completes $34,733 ESI deal

Crexendo, Inc. 2026: Revenue $14.87M, EPS $0.03— 10-Q Summary

Crexendo, Inc. reported its Q1 2026 results, showing a significant revenue increase of 77.5% year-over-year to $14.87M, primarily driven by the acquisition of ESI and organic subscriber growth. Despite revenue growth, net income and diluted EPS saw declines compared to the prior year quarter. …

Crexendo (CXDO) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

BRIEF-Crexendo Q2 Revenue USD 24.6 Million Vs. IBES Estimate USD 24.6 Million

Crexendo reported its Q2 revenue at USD 24.6 million, which matched the IBES estimate of USD 24.6 million. The article, originating from Reuters and distributed via TradingView, provides a brief financial update on the company's performance.

Exelixis, Inc. $EXEL Shares Sold by Private Client Services LLC

Private Client Services LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 40.9% in the second quarter, selling 19,576 shares. Despite this, Exelixis reported strong quarterly earnings of $0.87 per share, surpassing estimates, with revenue increasing 10% year over year to $610.81 million. The …

Exelon Secures More Than $1 Billion in Customer Protections Through Pioneering Transmission Security Agreements

A Cornerstone of The Exelon Promise, Transmission Security Agreements Shield Families and Small Businesses from Unfair Cost Shifts, Including Those Driven by Data Centers, Amid Power Generation Shortfalls CHICAGO, August 04, 2026--(BUSINESS WIRE)--Exelon has secured more than $1 billion in customer protections through pioneering …

Exelon Agreements Require Data Centers to Cover Projected Grid Costs

Exelon has secured over $1 billion in customer protections through Transmission Security Agreements (TSAs), which mandate that large new energy users, including data centers, cover their projected transmission service costs. This initiative is part of the "Exelon Promise" to shield families and small businesses …

Exelon (EXC) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 30, 2026, at 10 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Ryan Brown President and Chief Executive Officer - Calvin Butler Chief Financial Officer - Jeanne Jones President and Chief Executive Officer of …

Exelon Corporation Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next

Exelon Weeds Out Data Center Pipeline

Exelon has significantly reduced its estimates for data center growth within its service areas, culling speculative projects to focus on durable growth. The utility now anticipates 36 gigawatts of data center work, down from over 60 GW three months prior, with 11 GW in …

Exelixis Inc expected to post earnings of 79 cents a share - Earnings Preview

Exelixis Inc. is anticipated to report earnings of 79 cents per share. This information is provided as an earnings preview from Reuters, accessible via TradingView. The full article is available with unlimited access on TradingView.

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in Lexeo Therapeutics (NASDAQ:LXEO) by 9.7% in the first quarter, selling over 533,000 shares but still retaining a significant holding. Meanwhile, other institutional investors like Affinity Asset Advisors and Orbimed Advisors increased their positions in the clinical-stage …